Sandbox Reserved 1769
Sodium-taurocholate Co-transporting Polypeptide
ContentsIntroductionSodium-taurocholate Co-transporting Polypeptide (NTCP) is a member of the solute carrier membrane transport protein family. It is found within the membrane of  hepatocytes, and its primary role is to facilitate the transport of bile salts into hepatocytes from the bloodstream (Figure 1).[1] This is important because 90% of human bile salts are recycled daily, so the function of NTCP is critical in providing bile acids to solubilize fats for digestion. In addition to transporting bile acids into the cytoplasm of hepatocytes, NTCP also serves as an entry point receptor for Hepatitis B (HBV) and Hepatitis D (HDV) viruses (Figure 2).[2]  StructureNTCP is a transmembrane protein found in hepatocyte cells. It consists of nine transmembrane alpha helices, with the N-terminus located on the extracellular side of the plasma membrane and the C-terminus located on the intracellular side (Figure 3). The transmembrane helices are connected by short loops as well as extracellular and intracellular alpha helices that lie nearly parallel to the membrane.[2] Structures of NTCP were determined by cryogenic electron microscopy (Cryo-EM) of NTCP in complex with antibodies or nanobodies, which served to stabilize two known conformational states of NTCP. [1] [2] [3] [4] These complexed antibodies/nanobodies have been removed from all structures shown on this page.  DomainsNTCP contains two characteristic domains: the core and panel domains (Figure 3). Movement of these two domains allows recognition and transport of bile acids into hepatocytes.
Proline/Glycine HingeGlycine and proline residues in the connecting loops and extra- (ECH) and intracellular helices (ICH) (Figure 3) act as hinges in the mechanism of bile salt uptake. This flexibility allows separation of the core and panel domains, creating a pore open to the extracellular space and exposing critical Na+ binding sites. Once substrate binds the open-pore state, this hinge allows the transition to close this pore relative to the extracellular side and open to the cytoplasmic side, thus allowing release of substrate into the cell.[1] Sodium Binding SitesTo transport a single bile salt from the blood to the cytoplasm of the hepatocyte, two sodium ions must bind to NTCP in the open-pore state, using two sodium binding sites.[4] The residues in the first sodium binding site include S105, N106, T123, and E257. The residues in the second sodium binding site include Q68 and Q261. Mutations to these significant residues inhibit the binding of sodium ions, and consequently, inhibit the transport of bile salts by NTCP.[4] Secondary active transport is used, as the transport of bile acids into the cell is thermodynamically unfavorable, but is coupled with the favorable transport of two sodium into into the cell to make the overall process thermodynamically favorable.[1] When the bile salts are released into the cell, NTCP transitions to the inward facing state, where the pore is now closed to the extracellular side. FunctionMechanism of Bile Salt Uptake NTCP utilizes secondary active transport to uptake bile salts from blood plasma into the cytoplasm of liver cells (Figure 4). The transport of one bile salt is driven by the downhill transport of 2 Na+ ions along sodium’s electrochemical gradient. Liu et al. proposes a mechanism in which two bile salts and two Na+ ions bind to the open-pore state (Figure 4a), but only one bile salt (along with two Na+ ions) is released into the cytoplasm. After all substrates are bound, the conformational change from the open-pore state to the inward facing state is driven by the energetics of the favorable transport of Na+ ions. The inward facing state (Figure 4b) allows release of one bile salt and two Na+ ions the cytoplasm. In this conformation, the pore closes off relative to the extracellular side and opens to the cytoplasmic side.[2] Afterwards, the remaining bile salt bound to NTCP shifts to the position the previous bile salt occupied, and the process repeats itself.[4] Secondary active transport The inherent amiphipathicity of bile acids allows passage through NTCP’s amphipathic pore (Figure 5) .gif) . Mechanism of HBV/HDV InfectionAfter binding to NTCP in the open-pore state, the viruses remain bound until low bile salt levels in the blood shift equilibria enough that endocytosis of the virus occurs. Once inside the cell, the viral genetic information is released. The exact mechanism of how HBV and HDV bind to NTCP is not certain, two critical sites on NTCP for HBV/HDV binding have been identified: residues 84-87 and 157-165. An additional single-nucleotide polymorphism was discovered in East Asia involving residue 267 being mutated from serine to phenylalanine. This mutation prevented HBV/HDV infection. Another mutation, replacing L27, L31, and L35 with tryptophan residues, blocks the preS1 binding site, preventing HBV/HDV infection. Myristoylation of the HBV/HDV capsid is also vital for recognition by NTCP, as well as residues 8-17 on HBV/HDV (sequence: NPLGFFPDHQ)[3]. Two mechanisms have been proposed for how HBV/HDV binds to NTCP. The first mechanism involves binding of the myristoyl group to the host cell membrane, while residues 8-17 interact with NTCP residues 157-165. The second mechanism involves binding of the myristoyl group with residues 157-165 in the pore.[6] Medical RelevanceBile salts are derived from cholesterol, and they serve an important role in the mechanical digestion of fats and ultimately facilitate the chemical digestion of lipids.[7] Their amphipathicity allows them to solubilize hydrophobic fats for transport in aqueous bodily fluids.[7] Without bile salts, fats would spontaneously separate out of the aqueous solution in the duodenum and would not be accessible to pancreatic lipase for breakdown. Proper fat digestion requires both pancreatic lipase and bile; thus, NTCP's function in recycling bile salts is critical.[7] Additionally, bile acids play a major role in the regulation of lipid and energy metabolism. In mice, targeting NTCP-mediated bile acid was shown to treat obesity and obesity-related hepatosteatosis through the simultaneous dampening of intestinal fat absorption and increasing energy expenditure.[8] Insight into NTCP's structure and function has implications for therapeutic treatment of HBV/HDV infection. For example, the inhibitory effect of therapeutic antibody Nb87 on myr-preS1 binding shows potential for therapeutics that stabilize NTCP inward facing state as allosteric inhibitors of viral cell entry. [6] There have been various studies attempting to identify molecules that inhibit HBV/HDV binding of NTCP while maintaining NTCP's transporter activity. One study has identified a ciclosporin derivative that has the capability to prevent HBV binding while still allowing NTCP to transport bile salts. [9] This small molecule is the first to successfully prevent infection against multiple HBV genotypes without hindering normal NTCP activity, highlighting the fact that anti-HBV activity can remain separate from NTCP function.[9] Future studies will work to identify more effective and safe ways to prevent infection without harming normal NTCP function.
| ||||||||||||
References
Student Contributors
- Ben Minor
- Maggie Samm
- Zac Stanley
